Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in advanced pancreatic cancer
NCT05100329Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in pancreatic cancer (PC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05100329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100329.